SPC 2996

Drug Profile

SPC 2996

Alternative Names: LNA antisense molecule against Bcl-2 - Santaris; SPC-2996

Latest Information Update: 19 Aug 2009

Price : $50

At a glance

  • Originator Santaris Pharma
  • Class Antineoplastics; Oligonucleotides
  • Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Burkitt's lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 14 Jul 2009 Discontinued - Phase-I/II for Chronic lymphocytic leukaemia in Denmark (IV)
  • 14 Jul 2009 Discontinued - Preclinical for Solid tumours in Denmark (IV)
  • 14 Jul 2009 Discontinued - Phase-I/II for Non-Hodgkin's lymphoma in Denmark (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top